“ … it drives home the point that the FDA can react relatively quickly to real-time changes in this pandemic by looking at the wide variety of data sources available to it, including previous approvals, peer-reviewed studies, and perhaps most importantly, high-quality real-world data reflecting the moment we are in fighting this ever-changing virus."
Mark Cameron, PhD, recently commented to Consumer Affairs magazine about FDA approval of vaccines for teens between 12 and 15. The FDA also shortened the time frame between primary vaccinations and booster shots.
The FDA has taken steps to accelerate access to vaccines to children and teens:
- Amending the emergency use authorization (EUA) for the Pfizer-BioNTech vaccine to 12-15-year-olds.
- Shortening the time between a primary vaccination of the Pfizer vaccine and a booster dose to five months.
- Allowing for a third primary series dose for certain immunocompromised children 5-11 years of age.
Read the full story here.